Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BYNature Medicine

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial

  • Johann K Bauersachs1
  • Scott David Solomon2
  • Stefan D. Anker3
  • Isabel Antorrena4
  • Rudolf A. de Boer5
  • Gerasimos S Filippatos6
  • Tim Friede7,8
  • Wilfried Hauke9
  • Piotr P. Ponikowski10
  • Orly Vardeny11
  • Rebecca Altschul12
  • Michael Gamborg12
2 more authors
  • Kasper Vinther12
  • Thomas Thum13,14
14 affiliations
  1. 1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
  2. 2Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
  3. 3Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Charité Universitätsmedizin, Berlin, Germany
  4. 4Department of Cardiology, La Paz University Hospital, Research Institute IdiPAZ, Madrid, Spain
  5. 5Department of Cardiology, Erasmus University Medical Centre, Rotterdam, The Netherlands
  6. 6Department of Cardiology, Athens University Hospital Attikon, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
  7. 7Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany
  8. 8German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony, Göttingen, Germany
  9. 9Cardior Pharmaceuticals GmbH, a Novo Nordisk company, Hannover, Germany
  10. 10Institute of Heart Diseases, University Hospital, Medical University Wroclaw, Wroclaw, Poland
  11. 11University of Minnesota Medical School, Minneapolis, MN, USA
  12. 12Novo Nordisk A/S, Søborg, Denmark
  13. 13Cardior Pharmaceuticals GmbH, a Novo Nordisk company, Hannover, Germany. [email protected]
  14. 14Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany. [email protected]
Open at sourcePDFDOICite

Abstract

MicroRNA-132 (miR-132) is a central regulator of adverse cardiac remodeling. Here we evaluated CDR132L, a synthetic antisense oligonucleotide miR-132 inhibitor, in a multinational, randomized, double-blind, placebo-controlled phase 2 trial (HF-REVERT) in patients with recent myocardial infarction (MI) and left ventricular (LV) systolic dysfunction. Within 3–14 days after MI, 294 patients were randomized to receive CDR132L 5 mg kg −1 , CDR132L 10 mg kg −1 or placebo as three intravenous doses at 4-week intervals plus guideline-directed therapy. In total, 280 patients (245 men and 35 women) who received at least one dose of the study drug were included in the modified intention-to-treat population. CDR132L was well tolerated, with no hepatic, renal, hematologic or cardiac toxicity signals. The primary endpoint—the percentage change in LV end-systolic volume index at 6 months—improved in all groups but did not differ significantly between the CDR132L groups (5 mg kg −1 and 10 mg kg −1 ) and the placebo group. Secondary endpoints, including LV ejection fraction, global longitudinal strain and N-terminal pro B-type natriuretic peptide, were also not significantly different between the CDR132L and placebo groups. Prespecified exploratory analyses suggested potential benefits of CDR132L treatment in patients with advanced adverse remodeling at baseline, supporting further evaluation of CDR132L, including in chronic heart failure conditions. ClinicalTrials.gov: NCT05350969 .

Related

  1. ECG-Derived Synthetic Left Ventricular Mechanics Predict Mortality After Acute Myocardial Infarction and Fatal Myocardial Infarction in the General Population
    D. Corsi, J. Furst, A. D. Jamthikar +8
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  2. Impact of hypertriglyceridemia on right ventricular deformation in patients with left ventricular myocardial infarction: a cardiac magnetic resonance imaging study
    Yi Shu, Ting Fang, Zhenlin Li +2
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  3. Factors associated with 30-day mortality in patients with post-myocardial infarction ventricular septal rupture: a retrospective cohort study
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Mechanical circulatory support strategy in post-myocardial infarction ventricular septal defect repair.
    Caroline A Magro, Caroline Snyder, Katherine Phillips +4
    JTCVS openPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  5. ST-Segment Elevation Myocardial Infarction Secondary to Aortic Root Thrombosis in a Patient With a Left Ventricular Assist Device
    Umama Gorsi, Julia Kumar, Nathan Kim +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{bauersachs2026microrna,
  title = {{The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial}},
  author = {Johann K Bauersachs and Scott David Solomon and Stefan D. Anker and Isabel Antorrena and Rudolf A. de Boer and Gerasimos S Filippatos and Tim Friede and Wilfried Hauke and Piotr P. Ponikowski and Orly Vardeny and Rebecca Altschul and Michael Gamborg and Kasper Vinther and Thomas Thum},
  journal = {Nature Medicine},
  year = {2026},
  month = may,
  doi = {10.1038/s41591-026-04408-4},
  url = {https://doi.org/10.1038/s41591-026-04408-4},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
AU  - Johann K Bauersachs
AU  - Scott David Solomon
AU  - Stefan D. Anker
AU  - Isabel Antorrena
AU  - Rudolf A. de Boer
AU  - Gerasimos S Filippatos
AU  - Tim Friede
AU  - Wilfried Hauke
AU  - Piotr P. Ponikowski
AU  - Orly Vardeny
AU  - Rebecca Altschul
AU  - Michael Gamborg
AU  - Kasper Vinther
AU  - Thomas Thum
PY  - 2026
DA  - 2026/05/10
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04408-4
UR  - https://doi.org/10.1038/s41591-026-04408-4
AB  - MicroRNA-132 (miR-132) is a central regulator of adverse cardiac remodeling. Here we evaluated CDR132L, a synthetic antisense oligonucleotide miR-132 inhibitor, in a multinational, randomized, double-blind, placebo-controlled phase 2 trial (HF-REVERT) in patients with recent myocardial infarction (MI) and left ventricular (LV) systolic dysfunction. Within 3–14 days after MI, 294 patients were randomized to receive CDR132L 5 mg kg −1 , CDR132L 10 mg kg −1 or placebo as three intravenous doses at 4-week intervals plus guideline-directed therapy. In total, 280 patients (245 men and 35 women) who received at least one dose of the study drug were included in the modified intention-to-treat population. CDR132L was well tolerated, with no hepatic, renal, hematologic or cardiac toxicity signals. The primary endpoint—the percentage change in LV end-systolic volume index at 6 months—improved in all groups but did not differ significantly between the CDR132L groups (5 mg kg −1 and 10 mg kg −1 ) and the placebo group. Secondary endpoints, including LV ejection fraction, global longitudinal strain and N-terminal pro B-type natriuretic peptide, were also not significantly different between the CDR132L and placebo groups. Prespecified exploratory analyses suggested potential benefits of CDR132L treatment in patients with advanced adverse remodeling at baseline, supporting further evaluation of CDR132L, including in chronic heart failure conditions. ClinicalTrials.gov: NCT05350969 .
SN  - 1078-8956
SN  - 1546-170X
SN  - 1744-7933
ER  -